Central Alerting System
View Alert

Originator: CMO Messaging

From: CMO Messaging

Issue date: 28-Nov-2022 10:58:13

This alert has been issued to:
  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • NHS Regional Offices
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive
  • Special Health Authorities
  • NHS Trusts (England) - Medical Director
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • Consultants in Communicable Diseases
  • CMO Urgent Messages - Recipients on Public Health Link
  • Director of Public Health
  • NHS Trusts (England) - Chief Executive
  • GP - Locum
  • NHS 111 and Out of hours providers
  • GP Practices
  • Community Pharmacy
  • Primary Care Networks
  • GP Practices 1

Action category: Action

Title: Treatments for Highest Risk Non-Hospitalised Patients (Adults and Children) with COVID-19

Broadcast content:
The published UK-wide policy has been updated, effective with immediate effect, following consideration of the updated COVID therapeutic guideline from the World Health Organization (WHO), a review of the latest available evidence (including pharmacokinetic and pharmacodynamic data) and the extension to the marketing authorisation for remdesivir to cover adults and children (of all ages) weighing 40kg and above who do not require supplemental oxygen and who are at risk of progressing to severe COVID-19.

The policy now provides access to the following antiviral treatment choices for eligible ‘highest risk’ non-hospitalised patients: nirmatrelvir/ritonavir (Paxlovid) (first line), remdesivir (second line) or molnupiravir (third line). Exceptionally, sotrovimab may be considered where the available antiviral treatments are deemed unsuitable, and its use is supported following multi-disciplinary team (MDT) assessment.

Additional information: NHS England and NHS Improvement Regional Offices: please cascade this alert to community pharmacy

Alert reference: CEM/CMO/2022/014


Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency